Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225677 · ClinicalTrials.gov registry record
Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis
A clinical trial of Cirrhosis, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT03225677 is a study of Cirrhosis that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 20 participants, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03225677, a study of Cirrhosis, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the rate and mechanisms of skeletal muscle protein synthesis and breakdown in cirrhotic patients by using multiple tracers and single muscle biopsies.
Conditions Studied
Interventions
- PROCEDURE blood draw and muscle biopsy
Study Locations (1)
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-03 |
| Est. Completion | 2027-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225677
The ClinicalTrials.gov registry entry for NCT03225677 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,409-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which blood draw and muscle biopsy is the first listed.
NCT03225677 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT03225677 about?
NCT03225677 is a clinical study titled "Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis". To determine the rate and mechanisms of skeletal muscle protein synthesis and breakdown in cirrhotic patients by using multiple tracers and single muscle biopsies.
What is the current status of trial NCT03225677?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2017-08-03. Estimated completion is 2027-09-30.
What conditions does trial NCT03225677 study?
This clinical trial studies the following conditions: Cirrhosis.
What interventions are being tested in trial NCT03225677?
The interventions under investigation include: blood draw and muscle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03225677?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03225677 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting
RECRUITING
-
LiverSleep: A Behavioral Sleep Intervention for Patients With Cirrhosis and Insomnia
RECRUITING · NA
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
RECRUITING · Phase 3
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.